A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to…
Read More »progression
First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based…
Read More »By tracking the changes in prostate cancer cells over time, researchers at the Johns Hopkins Kimmel Cancer Center have found…
Read More »